FindTrial
Sign In

Safety and efficacy of etomidate-propofol mixture in esophageal vein ligation in patients with cirrhosis

Safety and efficacy of etomidate-propofol mixture in esophageal vein ligation in patients with cirrhosis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018033
Enrollment
Unknown
Registered
2018-08-27
Start date
2018-09-01
Completion date
Unknown
Last updated
2018-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis

Interventions

Group 1:etomidate-propofol mixture
Group 2:propofol injection

Sponsors

The Third Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) obtained written consent; (2) cirrhosis patients in our hospital with EVL; (3) aged 18 to 75 years; (4) had not taken part in the other clinical trials.

Exclusion criteria

Exclusion criteria: (1) Patients with other important organ dysfunction: severe liver and kidney dysfunction, organic brain disease, NYHA Status > III, coagulation dysfunction, sick sinus syndrome, bradycardia (HR < 55 bpm); (2) Contraindication of etomidate or propofol; (3) Other conditions which researchers concern not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Blood Pressure;—

Secondary

MeasureTime frame
Heart Rate;SpO2;Comfortable Degree;Minimal hepatic encephalopathy;Recovery time;—

Countries

China

Contacts

Public ContactGong Chulian

The Third Affiliated Hospital of Sun Yat-sen University

gongchulian@163.com+86 13560210793

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026